{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:51:46Z","timestamp":1770972706479,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In-transit metastases (ITMs) are challenging to treat because of their heterogenous disease course and chronic, relapsing\u2013remitting nature. Specific factors associated with worse prognosis are poorly understood and not included in current American Joint Committee on Cancer classifications. An ITMs-specific classification system to aid treatment decisions and clinical trial design is lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study involved 142 patients (M 44%, F 56%; median age 70\u00a0years [interquartile range 62\u201377]) with ITMs from a single, cutaneous melanoma. Baseline melanoma and ITMs characteristics, disease progression, and survival outcomes were collected from a prospective database. The primary outcome was disease-specific survival (DSS). A subgroup analysis excluding stage IV disease at diagnosis was performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A longer ITMs-free interval was associated with a longer DSS (hazard ratio [HR] 0.99; 95% confidence interval [CI] 0.98\u20131.00;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.027). A higher number of ITMs and greater Breslow thickness was associated with a shorter DSS (HR 1.25; 95% CI 1.04\u20131.51;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.020 and HR 1.10; 95% CI 1.04\u20131.17;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001). No independent predictors of DSS were identified. On multivariable analysis, larger ITMs and synchronous regional disease correlated with a worse distant metastasis-free survival (HR 1.02; 95% CI 1.03\u20131.31;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.015 and HR 2.61; 95% CI 1.44\u20134.72;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002). Maximum threshold analysis selected the optimal cut-point for continuous variables: two lesions for number of ITMs and 30\u00a0mm for size at initial diagnosis, 2\u00a0mm for primary melanoma Breslow thickness, and 20\u00a0months for ITMs-free interval (time from primary melanoma diagnosis to ITMs onset), adjusted to 18\u00a0months for clinical relevance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients presenting with more than two and\/or &gt;30\u00a0mm ITMs at first diagnosis, short ITM-free interval (\u226418\u00a0months), and synchronous regional disease should be considered at higher risk for disease progression and death.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-025-18542-9","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T20:46:35Z","timestamp":1762807595000},"page":"2579-2590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Simplified Classification System for In-Transit Melanoma Metastases"],"prefix":"10.1245","volume":"33","author":[{"given":"Sofia","family":"Breeze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Garioch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny","family":"Nobes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-235X","authenticated-orcid":false,"given":"Marc","family":"Moncrieff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"18542_CR1","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","volume":"43","author":"A Testori","year":"2016","unstructured":"Testori A, Ribero S, Bataille V. Diagnosis and treatment of in-transit melanoma metastases. Eur J Surg Oncol. 2016;43:544\u201360.","journal-title":"Eur J Surg Oncol."},{"key":"18542_CR2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1245\/s10434-014-4100-0","volume":"22","author":"RL Read","year":"2015","unstructured":"Read RL, Haydu L, Saw RPM, Quinn MJ, Shannon K, Spillane AJ, et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol. 2015;22:475\u201381.","journal-title":"Ann Surg Oncol."},{"key":"18542_CR3","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.bjps.2020.03.007","volume":"73","author":"MC Lo","year":"2020","unstructured":"Lo MC, Garioch J, Moncrieff MD. Sequencing in management of in-transit melanoma metastasis: diphencyprone versus isolated limb infusion. J Plast Reconstr Aesthet Surg. 2020;73:1263\u20137.","journal-title":"J Plast Reconstr Aesthet Surg."},{"key":"18542_CR4","first-page":"472","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:472\u201392.","journal-title":"CA Cancer J Clin."},{"key":"18542_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol."},{"key":"18542_CR6","unstructured":"The jamovi project. jamovi [Internet]. 2023. Available from: [computer software]. Version 2.1. 2023. Retrieved from https:\/\/www.jamovi.org."},{"key":"18542_CR7","unstructured":"R Core Team. R: A Language and environment for statistical computing [Internet]. 2022. Available from: [computer software]. Version 4.1. 2022. Retrieved from https:\/\/cran.r-project.org. (R packages retrieved from CRAN snapshot 2023-04-07)."},{"key":"18542_CR8","unstructured":"R Studio Team. Integrated development for R [Internet]. 2020. Available from: [computer software]. Version 1.8. 2020. Retrieved from http:\/\/www.rstudio.com\/."},{"key":"18542_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-804217-5.00002-3","volume-title":"Clinical trials: study design, endpoints and biomarkers, drug safety, and FDA and ICH guidelines","author":"T Brody","year":"2016","unstructured":"Brody T. Clinical trials: study design, endpoints and biomarkers, drug safety, and FDA and ICH guidelines. Academic Press; 2016."},{"key":"18542_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc."},{"key":"18542_CR11","doi-asserted-by":"crossref","unstructured":"Harrison E, Drake T, Ots R. Finalfit: quickly create elegant regression results tables and plots when modelling [Internet]. R package. 2019. Retrieved from: https:\/\/cran.r-project.org\/packages=finalfit","DOI":"10.32614\/CRAN.package.finalfit"},{"key":"18542_CR12","unstructured":"Therneau TM, Lumley T. Survival: survival analysis [Internet]. 2019. Retrieved from: https:\/\/CRAN.R-project.org\/package=survival."},{"key":"18542_CR13","unstructured":"Kassambara A, Kosinski M, Biecek P, Fabian S. Survminer: drawing survival curves using \u2018ggplot2\u2019 [Internet]. R package. 2019. Retrieved from: https:\/\/CRAN.R-project.org\/package=survminer."},{"key":"18542_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187\u2013202.","journal-title":"J R Stat Soc."},{"key":"18542_CR15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2307\/2532740","volume":"48","author":"B Lausen","year":"1992","unstructured":"Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48:73\u201385.","journal-title":"Biometrics"},{"key":"18542_CR16","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/sim.2331","volume":"25","author":"P Royston","year":"2006","unstructured":"Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25:127\u201341.","journal-title":"Stat Med."},{"key":"18542_CR17","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635\u201348.","journal-title":"J Clin Oncol."},{"key":"18542_CR18","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199\u2013206.","journal-title":"J Clin Oncol."},{"issue":"2","key":"18542_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2022.10.027","volume":"88","author":"C Riquelme-Mc Loughlin","year":"2023","unstructured":"Riquelme-Mc Loughlin C, Sandoval-Clavijo A, de Tord MB, Boada A, Alos L, Garcia A, Carrera C, Malvehy J, Puig S, Toll A, Podlipnik S. Prognostic role of microsatellites in melanoma and implications in the American joint committee on cancer classification system: a cohort study. J Am Acad Dermatol. 2023;88(2):338\u201347.","journal-title":"J Am Acad Dermatol."},{"key":"18542_CR20","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1038\/s41379-020-0500-9","volume":"33","author":"MG Niebling","year":"2020","unstructured":"Niebling MG, Haydu LE, Lo SN, Rawson RV, Lamboo LGE, Stollman JT, et al. The prognostic significance of microsatellites in cutaneous melanoma. Mod Pathol. 2020;33:1369\u201379.","journal-title":"Mod Pathol."},{"issue":"5","key":"18542_CR21","doi-asserted-by":"publisher","first-page":"290","DOI":"10.6004\/jnccn.2024.0036","volume":"22","author":"SM Swetter","year":"2024","unstructured":"Swetter SM, Johnson D, Albertini MR, Barker CA, Bateni S, Baumgartner J, Bhatia S, Bichakjian C, Boland G, Chandra S, Chmielowski B. NCCN guidelines\u00ae insights: Melanoma: Cutaneous, version 2.2024: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2024;22(5):290\u20138.","journal-title":"J Natl Compr Cancer Netw."},{"key":"18542_CR22","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1245\/s10434-019-07691-3","volume":"26","author":"SJ Masoud","year":"2019","unstructured":"Masoud SJ, Hu JB, Beasley GM, Stewart JH 4th, Mosca PJ. Efficacy of talimogene laherparepvec (T-VEC) therapy in patients with in-transit melanoma metastasis decreases with increasing lesion size. Ann Surg Oncol. 2019;26:4633\u201341.","journal-title":"Ann Surg Oncol."},{"key":"18542_CR23","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/jso.25601","volume":"120","author":"AY Zhou","year":"2019","unstructured":"Zhou AY, Wang DY, McKee S, Ye F, Wen C-C, Wallace DE, et al. Correlates of response and outcomes with talimogene laherperpvec. J Surg Oncol. 2019;120:558\u201364.","journal-title":"J Surg Oncol."},{"key":"18542_CR24","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1245\/s10434-014-4072-0","volume":"22","author":"DJ Muilenburg","year":"2014","unstructured":"Muilenburg DJ, Beasley GM, Thompson ZJ, Lee J-H, Tyler DS, Zager JS. Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. Ann Surg Oncol. 2014;22:482\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"18542_CR25","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","volume":"24","author":"D McDermott","year":"2013","unstructured":"McDermott D, Haanen J, Chen TT, Lorigan P, Oday S. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2\u00a0years following treatment in a phase III trial (MDX010-20). Ann Oncol. 2013;24(10):2694\u20138.","journal-title":"Ann Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18542-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18542-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18542-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:39:10Z","timestamp":1770899950000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18542-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["18542"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18542-9","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}